Vepugratinib for low-grade non-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an oral medication (vepugratinib) that targets a specific gene change (FGFR3) found in some bladder cancers. It is for people with low-grade, non-invasive bladder cancer that has not spread into the muscle, to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have low-grade (non-invasive) bladder cancer that has not spread into the bladder muscle.
- Your tumor must have a specific change in the FGFR3 gene (mutation or fusion) — this is the target of the study drug.
- You should be well enough to carry out daily activities (able to walk and take care of yourself).
- You must not have had positive urine cytology (a test for cancer cells in urine) in the last 6 weeks.
- You must not have received chemotherapy or other treatments directly into the bladder in the last 8 weeks.
- You must not have had high-grade bladder cancer or carcinoma in situ in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
This expanded access program provides the investigational drug vepugratinib to people with advanced cancers (especially bladder cancer) that have a specific genetic change (FGFR3 mutation) and who have run out of standard treatment options. The goal is to give access to a potential new therapy outside of a clinical trial.
This trial tests a new pill, dabogratinib, for people with low grade cancer in the upper urinary tract (the tubes that carry urine from the kidneys to the bladder). It may help shrink or control the cancer without needing surgery to remove the kidney.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.